title: Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma.
authors.affiliation: Department of Oncology, Istituto Oncologico Veneto (IOV - IRCCS), Padova, Italy.
authors.forename: Zora
authors.initials: Z
authors.lastname: Baretta
authors.forename: Rodrigo Santa Cruz
authors.initials: RS
authors.lastname: Guindalini
authors.forename: Galina
authors.initials: G
authors.lastname: Khramtsova
authors.forename: Olufunmilayo I
authors.initials: OI
authors.lastname: Olopade
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab